Glycosylation status of vitamin D binding protein in cancer patients

Protein Science

Volumn 18, Issue 10, 2009, Pages 2036-2042

  Rehder, Douglas S ^a   Nelson, Randall W ^a   Borges, Chad R ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cancer; GcMAF; Glycosylation; Vitamin D binding protein

Indexed keywords

MACROPHAGE ACTIVATING FACTOR; TRISACCHARIDE; VITAMIN D BINDING PROTEIN;

ARTICLE; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; GLYCOSYLATION; HUMAN; HYPOTHESIS; IMMUNOASSAY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

FEMALE; GLYCOSYLATION; HUMANS; IMMUNOASSAY; MACROPHAGE-ACTIVATING FACTORS; MALE; NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRISACCHARIDES; VITAMIN D-BINDING PROTEIN;

EID: 70349473231     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.214     Document Type: Article

References (43)

1. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y (2008) Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor. Gc MAF Cancer Immunol Immunother 57:1007-1016.
2. Yamamoto N, Suyama H, Yamamoto N (2008) Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor. Gc MAF Transl Oncol 1:65-72.
3. Yamamoto N, Suyama H, Yamamoto N, Ushijima N (2008) Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 122:461-467. (Pubitemid 350234736)
4. Yamamoto N (1996) Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Mol Immunol 33:1157-1164.
5. Yamamoto N, Homma S (1991) Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88:8539-8543. (Pubitemid 21915392)
6. Yamamoto N, Homma S, Millman I (1991) Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147:273-280.
7. Yamamoto N, Kumashiro R (1993) Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794-2802. (Pubitemid 23264531)
8. Borges CR, Jarvis JW, Oran PE, Nelson RW (2008) Population studies of vitamin d binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent o-glycosylation patterns. J Proteome Res 7:4143-4153.
9. Borges CR, Jarvis JW, Oran PE, Rogers SP, Nelson RW (2008) Population studies of intact Vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech 19:167-176.
10. Coppenhaver DH, Sollenne NP, Bowman BH (1983) Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). Arch Biochem Biophys 226:218-223.
11. Svasti J, Bowman BH (1978) Human group-specific component. Changes in electrophoretic mobility resulting from vitamin D binding and from neuraminidase digestion. J Biol Chem 253:4188-4194. (Pubitemid 8380639)
12. Svasti J, Kurosky A, Bennett A, Bowman BH (1979) Molecular basis for the three major forms of human serum vitamin D binding protein (group-specific component). Biochemistry 18:1611-1617. (Pubitemid 9183291)
13. Viau M, Constans J, Debray H, Montreuil J (1983) Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. Biochem Biophys Res Commun 117:324-331. (Pubitemid 14216882)
14. Speeckaert M, Huang G, Delanghe JR, Taes YE (2006) Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372:33-42. (Pubitemid 44286753)
15. Yamamoto N, Naraparaju VR, Urade M (1997) Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57:295-299. (Pubitemid 27036609)
16. Korbelik M, Naraparaju VR, Yamamoto N (1998) The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy. Br J Cancer 77:1009-1014. (Pubitemid 28101794)
17. Yamamoto N, Naraparaju VR, Asbell SO (1996) Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res 56:2827-2831. (Pubitemid 26175743)
18. Arnaud J, Constans J (1993) Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 92:183-188. (Pubitemid 23272286)
19. Kanan RM, Cook DB, Datta HK (2000) Lectin immunoassay for macrophage-activating factor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence for noninducible generation of Gc-MAF. Clin Chem 46:412-414.
20. Yamamoto N, Naraparaju VR, Orchard PJ (1996) Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis. Blood 88:1473-1478. (Pubitemid 26276825)
21. Nelson RW, Krone JR, Bieber AL, Williams P (1995) Mass spectrometric immunoassay. Anal Chem 67:1153-1158.
22. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW (2006) Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 5:1682-1687. (Pubitemid 44036142)
23. Kiernan UA, Nedelkov D, Nelson RW (2006) Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 5:2928-2934. (Pubitemid 44749211)
24. Kiernan UA, Nedelkov D, Niederkofler EE, Tubbs KA, Nelson RW (2006) High-throughput affinity mass spectrometry. Methods Mol Biol 328:141-150.
25. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW (2004) Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 4:1825-1829. (Pubitemid 38738336)
26. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW (2004) Selected expression profiling of full-length proteins and their variants in human plasma. Clin Proteomics J 1:7-16. (Pubitemid 41271306)
27. Kiernan UA, Tubbs KA, Gruber K, Nedelkov D, Niederkofler EE, Williams P, Nelson RW (2002) High-throughput protein characterization using mass spectrometric immunoassay. Anal Biochem 301:49-56. (Pubitemid 34113677)
28. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, McConnell E, Nelson RW (2003) Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2:191-197. (Pubitemid 37099055)
29. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW (2002) Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem Biophys Res Commun 297:401-405. (Pubitemid 35216185)
30. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW (2003) Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 537:166-170. (Pubitemid 36246696)
31. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U (2008) Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circulation: Heart Failure 1:258-264.
32. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, Williams P, Nelson RW (2001) Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 73:3294-3299. (Pubitemid 32880612)
33. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW (2003) Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 44:630-639. (Pubitemid 37279713)
34. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW (2005) High-throughput MS-based protein phenotyping: application to haptoglobin. Proteomics 5:5002-5007. (Pubitemid 43016919)
35. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW (2006) Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal Chem 78:3271-3276. (Pubitemid 43748969)
36. Tubbs KA, Nedelkov D, Nelson RW (2001) Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal Biochem 289:26-35. (Pubitemid 32121565)
37. Nedelkov D (2005) Population proteomics: addressing protein diversity in humans. Expert Rev Proteomics 2:315-324.
38. Nedelkov D (2008) Population proteomics: investigation of protein diversity in human populations. Proteomics 8:779-786.
39. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW (2005) Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 102:10852-10857. (Pubitemid 41105956)
40. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW (2006) Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol Cell Proteomics 5:1811-1818. (Pubitemid 44688190)
41. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW (2007) Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 6:1183-1187. (Pubitemid 47099228)
42. Nedelkov D, Tubbs KA, Niederkofler EE, Kiernan UA, Nelson RW (2004) High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal Chem 76:1733-1737. (Pubitemid 38338422)
43. Hermanson GT, Krishna Mallia A, Smith PK (1992) Immobilized affinity ligand techniques. San Diego, CA: Academic Press.